Mie University Graduate School of Medicine Researcher Reports Research in Liver Cancer (Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab).

Předmět:	PROTEIN-tyrosine kinase inhibitors DRUG therapy VASCULAR endothelial growth factor antagonists END of treatment PSOAS muscles
Zdroj:	Immunotherapy Weekly; 10/22/2024, p536-536, 1p
Abstrakt:	A recent study conducted at Mie University Graduate School of Medicine in Japan explored the prognostic significance of Psoas Muscle Index (PMI) in patients with unresectable hepatocellular carcinoma (uHCC) undergoing different drug therapies. The research found that a low PMI was a significant prognostic factor for overall survival (OS) in patients receiving both lenvatinib (LEN) and atezolizumab plus bevacizumab (ATZ-BEV) therapies. The study suggested that ATZ-BEV therapy may be more beneficial for patients with low PMI and advanced stages of HCC. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu